If He's Doing Any of These 11 Things, the Relationship Might Be Over for Him, Psychologists Warn
You can't read your partner's mind, so it may sometimes seem like a mystery to you why he's acting the way he is. Maybe the way he's texting you has changed suddenly, or he's started hanging out with his friends a lot more. If you've noticed that your boyfriend or husband is acting differently, you may have cause to worry that a breakup is imminent. To get to the bottom of the potential may be over for him, Parade consulted two expert psychologists., clinical psychologist, professor and mental health speaker, as well as , neuropsychologist and director of Comprehend the Mind, weigh in on how small shifts in a man's behavior may indicate that he's .Of course, if a man starts exhibiting these signs, it "doesn't always mean a breakup is inevitable," says Dr. Hafeez, adding, "But it's important not to ignore them."So if you do notice the signals mentioned below, it's likely time for a conversation. "If you are aware of the [signs], you should think about initiating a candid and sympathetic dialogue," Dr. Brown says. That way, the couple can gain "deeper insight and go around the matter in a way that leads to clarification," he says.Here's what they say you should be paying attention to if you're concerned about your relationship.Related:
Why Is It Sometimes Hard To Tell if He's Over You?
If you've ever had a breakup come seemingly out of the blue, you're not alone. Dr. Brown says that the ways men and women tend to communicate can often lead to misinterpretations."Women are usually on the lookout for the non-verbal messages and the emotional context. Men often demonstrate their emotions through actions instead of feelings," he says. "The difference in their understanding leads to the confusion about partners' real emotions."Additionally, Dr. Hafeez says that you may miss key signs because your partner has continued "to act polite or affectionate out of habit, even when their feelings have faded." She adds that instead of communicating directly, "they may quietly create distance, which sends mixed signals."But it's time to decode those signals.Related:
How Does a Man Act When He Wants To End a Relationship?
Because men often show their feelings through their actions, Dr. Brown says that "usually, some of the signs give it away" if a man wants to end his relationship. "Emotional explosions are a sign of being deeply unsatisfied," he explains. "Also, showing indifference or showing anger towards things that were very much cared for before."It may feel like "he is mentally somewhere else... even when you're in the same room," Dr. Hafeez says.And those indications are just the tip of the iceberg.Related:
11 Signs the Relationship Is Over for Him, According to Psychologists
1. Emotional detachment
Dr. Hafeez says that something to watch out for is a general lack of interest or attention from your partner—like if "he no longer asks about your day" or he doesn't "[seem] invested in how you feel," she explains.
2. Change in communication
Pay attention to a sudden reduction in communication. "If they retort with minimal words or act uninterested, they might be distancing themselves emotionally," Dr. Brown says. "He might text back less often and with a lower degree of emotion, which indicates that he is emotionally disconnected."
3. Easy irritation
Dr. Hafeez says that if your partner "seems more easily irritated" or is "reacting strongly" to things that didn't previously bother him, that is another red flag.Related:
4. Not planning for the future
According to Dr. Brown, if your partner starts "asking to delay future plans" or "dodging serious conversations about the relationship's future," that may signal that he's "prepared to continue life without that relationship." So take note if there's "a lack of long-term plans" in your relationship, he says.
5. Opting out of shared routines
Many couples have shared routines like watching certain TV shows together or participating in weekend activities as a duo. So Dr. Hafeez says it could be a red flag if he starts skipping those rituals. It "can signal emotional withdrawal," she adds.
6. Seeking outside support
"Sharing personal issues with friends instead of you could mean they want support from outside of the relationship," Dr. Brown says. Of course, it's good for both halves of the couple to have strong friendship bonds. But if there's a significant shift in the way your partner confides in you, it may be worth paying closer attention to that.
7. Desire to be alone
Just like it is with having friends, it's also OK to not do everything together as a couple. But if he starts always wanting to be away from you—take note."If he tends to dedicate more time to his hobbies and hangs out without a partner, it could probably mean that he is longing for autonomy," Dr. Brown says. "Disruptions to their schedules could be the first signs of a wish for autonomy. So, when they do late shifts or are away with friends more frequently, pay attention to this aspect."
8. Being secretive about his phone
Dr. Hafeez says if your partner suddenly "starts taking calls in private" when he didn't before, that behavior should stand out to you. Keeping secrets—particularly around their phone and social media use—is something Dr. Brown flags as well. "It could be a sign of emotional disentanglement," he warns.Related:
9. Changes in your sex life
Dr. Brown says that "a disinterest in making physical contact" or an "adjustment in sex" from your partner are other signs to watch out for. "If the emotional warmth is absent or they are trying to spend less time together, it might mean they are feeling disconnected," he explains.
10. Increased interest in self-growth
On its own, it's not necessarily a bad thing if your partner wants to improve his physical or mental health—but if it comes out of nowhere or in combination with some of these other signs, then it may definitely be something worth noting.Dr. Hafeez says that he may start talking about "personal growth" or "needing time alone," which she says can be a concern, especially if these topics weren't a focus before."And Dr. Brown explains that "an increased focus on self-care—for instance, by hitting the gym or changing the way they look—could mean they are trying to be independent."
11. Frequent criticisms
If your partner suddenly starts criticizing you a lot, it could be a sign that he's unhappy in the relationship."If they frequently underline your insignificant flaws, it could be that they have some major issue to deal with," Dr. Brown says. "Regular complaints about the relationship ... are important indicators of that too."If you do notice any of the aforementioned signs and you're concerned, Dr. Hafeez says the next step is having "an honest conversation where you express your concerns" as well as asking your partner "how he truly feels." Then you can get clarity either way and start to "open the door to healing," she adds.Up Next:Sources:
Dr. Adolph "Doc" Brown, III, is a clinical psychologist, professor and mental health speaker. Find him on Instagram @adolphbrown.
Dr. Sanam Hafeez is a neuropsychologist anddirector of Comprehend the Mind. Find her on Instagram @drsanamhafeez.
If He's Doing Any of These 11 Things, the Relationship Might Be Over for Him, Psychologists Warn first appeared on Parade on Aug 5, 2025
This story was originally reported by Parade on Aug 5, 2025, where it first appeared.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Mom says infant may have rare tick-borne disease
A Massachusetts mom says her infant daughter may be the patient that state health officials recently said is under investigation for contracting a rare tick-borne virus infection. "Public health officials are investigating preliminary results of a Powassan virus infection in a Martha's Vineyard resident," Barnstable County said in a press release Tuesday, without identifying the resident. Barnstable County, which comprises the 15 towns of Cape Cod and sits just north of Martha's Vineyard, said that according to data from the Centers for Disease Control and Prevention, there has been just one other known case of Powassan virus in the area in the last 20 years and only three total Powassan virus cases in Massachusetts this year. The CDC notes there are currently 24 reported Powassan cases nationwide. Tiffany Sisco, who declined to be interviewed by ABC News, told Boston ABC station WCVB that she found a tick on her 5-week-old daughter Lily Belle Sisco during an outdoor walk, and despite removing it, she noticed Lily developed symptoms a week later. "I found this tiny, tiny, tiny [tick], the teeniest one on her ankle," Sisco said. "I picked it off. A week later, she started getting a fever of 102 [degrees Fahrenheit]. I said, 'I'm taking her right in.'" What is the Powassan virus? Powassan virus is a disease or illness caused by the Powassan virus and is mostly spread by infected ticks that have the Powassan virus or deer tick virus, according to the CDC. The ticks may get infected when they feed on other animals that have the virus, such as groundhogs, mice, squirrels or other rodents. ER visits for tick bites near record levels this summer across US Although considered rare, the CDC notes that Powassan infections have been increasing in recent years, with most infections occurring in northeast states and the states around the Great Lakes region in the spring and fall, when ticks are most active. The Powassan virus can also be transmitted by blood, so anyone who has the virus should not donate blood or bone marrow for at least 120 days after infection. What are the symptoms of Powassan virus and how is it treated? Symptoms of Powassan virus include headache, fever, vomiting and weakness, according to the CDC. The virus can also cause severe disease, the agency states, including inflammation of the brain or inflammation of the membranes around the brain or spinal cord. Symptoms of a severe infection may include confusion, loss of coordination, trouble speaking, and seizures. Some people, such as children, older adults and people with weakened immune systems, may be at higher risk of developing severe symptoms. People with Powassan virus may require fluids, pain medications and rest to alleviate symptoms, but anyone with severe disease may need to be admitted to a hospital for further treatment. What to know about tick-borne illnesses How to prevent tick-borne illnesses There are currently no medications or vaccines to prevent a Powassan virus infection, according to the CDC. However, there are precautions you can take to protect you and your family from tick bites and any subsequent infections. These include: Applying EPA-registered insect repellents. Wearing long-sleeved clothing and pants. Avoiding bushy and wooded areas. Checking for ticks thoroughly and remove any after spending time outdoors. The CDC also advises treating outdoor clothing and gear with products containing 0.5% permethrin, an insect repellent, which will "remain protective through several washings." Solve the daily Crossword
Yahoo
20 minutes ago
- Yahoo
More than 400 indirect deaths linked to LA wildfires, study suggests
More than 400 additional deaths are estimated to be linked to the wildfires that ravaged Los Angeles earlier this year, according to a new study. The figure, published on Wednesday in the medical journal JAMA, looks at deaths that have been attributed to factors caused by the wildfires, like poor air quality and delays in accessing healthcare. It is a higher figure than the official death count of 31 by the Los Angeles County, which tallied deaths caused directly by the fires. The study comes as hundreds of wildfires burn across the US and Canada, prompting air quality advisories in cities like Chicago, Buffalo and New York. The Palisades and Eaton fires tore through Los Angeles in January, destroying thousands of structures and leading to the evacuation of more than 100,000 Los Angeles residents. Why wildfires are becoming faster and more furious The far-reaching impacts of wildfire smoke – and how to protect yourself The latest study revealed that around 440 people are estimated to have died as a result of the wildfires between 5 January and 1 February. Researchers said they tallied the figure by looking at all deaths and their causes in Los Angeles during the period of the fires, and comparing it to similar data from previous years. The results show that there were nearly 7% more deaths during the wildfires. Some are attributed to lung and heart conditions exacerbated by smoke or stress, while others are more indirect - like delayed healthcare treatment for dialysis or cancer patients as a result of fire-related disruptions. The authors said that the findings underscore the need for officials to count both direct and indirect fatalities of wildfires and other climate-related emergencies when trying to quantify their impact. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies," the authors said, noting that their figures are provisional as there may have been additional fire-related deaths beyond the scope of the study. The BBC has reached out to Los Angeles County officials for comment on the study's findings. Another study released on Wednesday in JAMA that looked at the aftermath of the 2023 Maui wildfires showed that 22% of adults in the region had reduced lung function, and half displayed symptoms of depression. The fires, which broke out in August 2023 and were the worst to affect Hawaii in recent history, killed at least 102 people and destroyed more than 2,000 structures. The authors of the Maui study said their results show the need for "sustained clinical monitoring and community-based mental health supports" months after a climate disaster. A second study on the Hawaii fires suggests that Maui saw the highest suicide and drug overdose rates in the month of the 2023 wildfires. Wildfires have become more frequent in recent years as a result of climate change, driven by hotter and drier weather that fuels fire spread. In addition to directly threatening lives and structures, smoke from wildfires has been shown to have adverse health effects on people. Wildfire smoke has been found to be harmful to certain immune cells in the lungs, with a toxicity four times greater than particulates from other types of pollution. This can have a long-term impact on cardiovascular health, experts have said. Older people, pregnant women and young children, as well as those with underlying health conditions, such as heart disease or asthma, are more likely to get sick, experts say. But the smoke can also impact healthy adults. One dead and thousands evacuated as wildfire spreads in France Massive clouds of smoke blanket parts of California as Gifford fire grows Canadian wildfires prompt New York air quality alert Ten workers killed battling wildfires in Turkey
Yahoo
20 minutes ago
- Yahoo
Senseonics Holdings, Inc. Reports Second Quarter Financial Results
Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.6 million in the second quarter of 2025, an increase of 37% versus the second quarter of 2024, driven by 79% new patient growth in the U.S. over prior year Expanded direct-to-consumer (DTC) advertising campaign to drive further awareness and adoption of Eversense in the U.S., with the first month of enhanced campaign generating a 50% increase in leads over prior three-month average Completed transition of providers to Eon Care from the Nurse Practitioner Group (NPG), now with 38 providers to support patient access to insertions CMS updated the Medicare Physician Fee Schedule, providing reimbursement for a full year of usage with Eversense 365 as a medical benefit Entered into a commercial development agreement to integrate Sequel Med Tech's twiist™ automated insulin delivery (AID) system with Eversense 365, with launch expected in Q4 Raised $77.8 million in total gross proceeds, including $57.5 million in a public offering and $20.3 million from Abbott in a concurrent private placement, to fund the ongoing launch of Eversense 365 and continued development of pipeline products 'During the quarter we continued to drive a strong U.S. Eversense 365 launch focused on new patients, initiating enhanced DTC advertising in June to broaden actionable leads and enable acceleration in patients and revenue growth in the second half of the year,' said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. 'We advanced several other important strategic initiatives which drive uptake and advance our technology to position us for increased shareholder value while progressing the development of Gemini and Freedom.' Second Quarter 2025 Results:Total revenue for the second quarter of 2025 was $6.6 million compared to $4.9 million for the second quarter of 2024. U.S. revenue was $4.9 million for the second quarter of 2025 compared to $3.0 million for the second quarter of 2024, and revenue outside the U.S. was $1.7 million in the second quarter of 2025 compared to $1.9 million in the prior year period. Second quarter 2025 gross profit of $3.1 million compared to gross profit of $0.3 million for the second quarter of 2024. The increase in gross profit was primarily driven by increased margins on the 365-day product and a one-time gain as the result of previously expensed value-added tax recovered from prior years. Second quarter 2025 research and development expenses decreased by $3.1 million year-over-year, to $7.7 million (from $10.8 million). The decrease was primarily due to a reduction in clinical studies spend and consultant costs due to the completion of 365-day product trials. Second quarter 2025 selling, general and administrative expenses increased by $0.7 million year-over-year, to $9.7 million (from $9.0 million). The increase was primarily driven by higher sales commissions expenses due to an increase in consignment sales and an increase in personnel costs to support the Eon Care inserter network. Net loss was $14.5 million, or a $0.02 loss per share, in the second quarter of 2025 compared to net loss of $20.3 million, or a $0.03 loss per share, in the second quarter of 2024. Net loss decreased by $5.8 million primarily due to improved gross profit margins of Eversense 365 sales in the United States and the overall reduction in research and development costs. Full Year 2025 Financial OutlookSenseonics continues to expect full-year 2025 global net revenue to be approximately $34-38 million as we continue to roll out Eversense 365 to U.S. patients. The full-year 2025 financial outlook assumes approximately doubling of our global patient base during 2025, with approximately one-third of revenue generated in the first half of 2025 and two-thirds of revenue to be generated in the second half of 2025, second half revenue will be weighted to the fourth quarter due to once-a-year Eversense 365 reorder dynamics following its Q4 launch. The financial outlook takes into consideration current assumptions regarding: (i) refined visibility of the timeline and specifications for the regulatory approval and the plans for commercial transition to Eversense 365 outside the United States, (ii) projected plans with respect to spending on the DTC marketing campaign to generate additional leads, (iii) executing on other sales and marketing initiatives, (iv) anticipated utilization and impact of the patient assistance programs for Eversense 365, and (v) continued progress with the transition of reimbursement from Eversense E3 to Eversense 365. Gross margins are expected to increase throughout 2025, with 2025 gross margins between 32.5% and 37.5% for the full year. Cash used in operations in 2025 is expected to be approximately $60 million. Conference Call and Webcast Information:Company management will host a conference call at 4:30 pm (Eastern Time) today, August 6, 2025, to discuss these financial results and recent business developments. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at this link. Individuals interested in participating in the call via telephone may access the call by dialing +1-800-225-9448 (+1-203-518-9708 for those outside the U.S. or Canada) and referencing Conference ID SENSQ2. A replay of the call can be accessed on Senseonics' website under 'Investor Relations.' About SenseonicsSenseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. About EversenseThe Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see About Ascensia Diabetes CareAscensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity. Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: About PHC Holdings CorporationPHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 353.9 billion with global distribution of products and services in more than 125 countries. ©2025 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. Forward Looking StatementsAny statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue, gross margin, cash flow and global installed customer base projections, and global installed customer base and reorder assumptions, under the heading 'Full Year 2025 Financial Outlook,' statements regarding plans, timing and success of the commercial launch of the 365-day system and the adoption of, access to, or growth of use of Eversense, statements regarding future demand for Eversense, statements regarding development programs and next generation systems, statements regarding the collaboration with Sequel and the anticipated timing for commercial availability of an integrated twiistTM AID system with Eversense 365, the future regulatory approval and the potential to commercially launch Eversense 365 outside the U.S., and other statements containing the words "believe," 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the reliance on and execution of Ascensia Diabetes Care, the Company's commercialization partner for Eversense, uncertainties with respect to any additional commercial support that will be required for successful commercialization of Eversense, and other commercial initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics' and its partners' activities, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and future reports filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof. Senseonics Investor ContactJeremy FefferLifeSci Advisorsinvestors@ Senseonics Holdings, Consolidated Balance Sheets(in thousands, except share and per share data) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 31,518 $ 74,597 Restricted cash 315 315 Short term investments, net 94,894 — Accounts receivable, net 2,853 1,365 Accounts receivable, net - related parties 2,304 4,921 Inventory, net 4,714 4,421 Prepaid expenses and other current assets 4,990 5,819 Total current assets 141,588 91,438 Deposits and other assets 4,729 4,926 Property, equipment and intangible assets, net 3,957 4,074 Total assets $ 150,274 $ 100,438 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $ 2,269 $ 3,205 Accrued expenses and other current liabilities 9,883 13,636 Accrued expenses and other current liabilities, related parties 2,624 1,870 Notes payable, current portion, net — 20,138 Total current liabilities 14,776 38,849 Long-term debt and notes payables, net 35,230 34,703 Non-current operating lease liabilities 5,548 5,785 Total liabilities 55,554 79,337 Preferred stock and additional paid-in-capital, subject to possible redemption: $0.001 par value per share; 0 and 12,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024 — 37,656 Total temporary equity — 37,656 Commitments and contingencies Stockholders' equity (deficit): Common stock, $0.001 par value per share; 1,400,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 814,576,132 shares and 595,351,210 shares issued and outstanding as of June 30, 2025 and December 31, 2024 815 595 Additional paid-in capital 1,070,516 930,724 Accumulated other comprehensive loss 23 — Accumulated deficit (976,634 ) (947,874 ) Total stockholders' equity (deficit) 94,720 (16,555 ) Total liabilities, temporary equity and stockholders' equity (deficit) $ 150,274 $ 100,438 Senseonics Holdings, Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share data) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue, net $ 3,223 $ 778 $ 5,033 $ 1,367 Revenue, net - related parties 3,426 4,087 7,873 8,545 Total revenue 6,649 4,865 12,906 9,912 Cost of sales 3,528 4,567 8,280 9,279 Gross profit 3,121 298 4,626 633 Expenses: Research and development expenses 7,715 10,800 15,014 21,238 Selling, general and administrative expenses 9,729 8,991 17,423 17,119 Operating loss (14,323 ) (19,493 ) (27,811 ) (37,724 ) Other (expense) income, net: Interest income 973 1,190 1,648 2,574 Interest expense (1,145 ) (2,085 ) (2,574 ) (4,133 ) Gain on change in fair value of derivatives — 102 — 102 Other (expense) income (6 ) (1 ) (23 ) 17 Total other (expense) income, net (178 ) (794 ) (949 ) (1,440 ) Net Loss (14,501 ) (20,287 ) (28,760 ) (39,164 ) Other comprehensive loss Unrealized gain (loss) on marketable securities 26 (5 ) 23 4 Other comprehensive gain (loss) 26 (5 ) 23 4 Total comprehensive loss $ (14,475 ) $ (20,292 ) $ (28,737 ) $ (39,160 ) Basic net loss per common share $ (0.02 ) $ (0.03 ) $ (0.04 ) $ (0.06 ) Basic weighted-average shares outstanding 813,364,903 616,585,664 766,382,267 615,587,105 Diluted net loss per common share $ (0.02 ) $ (0.03 ) $ (0.04 ) $ (0.06 ) Diluted weighted-average shares outstanding 813,364,903 616,585,664 766,382,267 615,587,105